Zhong-Sen Qu1, Qing-De Zhang2, Liang Li3. 1. Department of Neurology, Shanghai Jiao Tong University Affiliated The Sixth People's Hospital Yi Shan Road 600, Shanghai 200233, China. 2. Department of Internal Medicine, Heze High Medical School Heze 274030, China. 3. Department of Neurology, Qingdao University Affiliated The Central Hospital Qingdao 266042, China.
Abstract
BACKGROUND: Cerebrovascular accident is an important cause of death in patients with chronic renal failure. METHODS: This study evaluated the interference of low-dose urokinase in peritoneal dialysis solution on uremic serum superoxide dismutase (SOD), malondialdehyde (MDA), nitric oxide (NO) and endothelin (ET) dynamics in patients with a cerebral infarction complicated by uremia. RESULTS: Both the urokinase and conventional treatment groups showed decreased SOD activities, increased MDA content, and elevated serum NO and ET levels at the initiation stage of treatment. Antiplatelet and cerebral protection therapy slightly reduced body MDA content and increased SOD activity at the early stage of treatment, and its effects on reducing serum NO and ET-1 are also limited. CONCLUSION: Our results revealed that a small amount of urokinase in peritoneal dialysis can reduce body MDA content, increase SOD activity and decrease serum levels of NO and ET-1 at the early stage of cerebral infarction complicated by uremia. We also found that continuous treatment for 8 weeks may provide a potential treatment of cerebral infarction complicated with uremia.
BACKGROUND:Cerebrovascular accident is an important cause of death in patients with chronic renal failure. METHODS: This study evaluated the interference of low-dose urokinase in peritoneal dialysis solution on uremic serum superoxide dismutase (SOD), malondialdehyde (MDA), nitric oxide (NO) and endothelin (ET) dynamics in patients with a cerebral infarction complicated by uremia. RESULTS: Both the urokinase and conventional treatment groups showed decreased SOD activities, increased MDA content, and elevated serum NO and ET levels at the initiation stage of treatment. Antiplatelet and cerebral protection therapy slightly reduced body MDA content and increased SOD activity at the early stage of treatment, and its effects on reducing serum NO and ET-1 are also limited. CONCLUSION: Our results revealed that a small amount of urokinase in peritoneal dialysis can reduce body MDA content, increase SOD activity and decrease serum levels of NO and ET-1 at the early stage of cerebral infarction complicated by uremia. We also found that continuous treatment for 8 weeks may provide a potential treatment of cerebral infarction complicated with uremia.
Authors: A P Fletcher; N Alkjaersig; M Lewis; V Tulevski; A Davies; J E Brooks; W B Hardin; W M Landau; M E Raichle Journal: Stroke Date: 1976 Mar-Apr Impact factor: 7.914
Authors: E Maggi; R Bellazzi; F Falaschi; A Frattoni; G Perani; G Finardi; A Gazo; M Nai; D Romanini; G Bellomo Journal: Kidney Int Date: 1994-03 Impact factor: 10.612
Authors: V Witko-Sarsat; M Friedlander; C Capeillère-Blandin; T Nguyen-Khoa; A T Nguyen; J Zingraff; P Jungers; B Descamps-Latscha Journal: Kidney Int Date: 1996-05 Impact factor: 10.612